Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: A proof of concept study

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2015, Pages 174-180

  Achuthan, S ^a   Ahluwalia, J ^a   Shafiq, N ^a   Bhalla, A ^a   Pareek, A ^b   Chandurkar, N ^b   Malhotra, Samir ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b Ipca Laboratories Ltd   (India)

Author keywords

arachidonic acid; clinical trial; healthy volunteers; hydroxychloroquine; platelet aggregation; thromboxane b2

Indexed keywords

11 OXOTHROMBOXANE B2; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; FIBRINOGEN; HYDROXYCHLOROQUINE; THROMBOXANE A2; ACETYLSALICYLIC ACID;

ADULT; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GOOD CLINICAL PRACTICE; HEMATOLOGICAL PARAMETERS; HUMAN; KRUSKAL WALLIS TEST; MALE; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE AGGREGATION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; NORMAL HUMAN;

ASPIRIN; CARDIOVASCULAR DISEASES; FIBRINOGEN; HEALTHY VOLUNTEERS; HUMANS; HYDROXYCHLOROQUINE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 84922624821     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414546324     Document Type: Article

References (34)

1. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997 ; 17 (10). 1859-1867
2. Pusch G, Feher G, Kotai K, et al. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol. 2008 ; 52 (6). 475-484
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999 ; 340 (2). 115-126
4. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (cirt). J Thromb Haemost. 2009 ; 7: 332-339
5. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin a1c, lipids, c-reactive protein, interleukin-6, and fibrinogen: A phase iib randomized, placebo-controlled trial. Circulation. 2012 ; 126 (23). 2739-2748
6. Jancinova V, Nosal R, Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res. 1994 ; 74 (5). 495-504
7. Cooke ED, Dawson MH, Ibbotson RM, Bowcock SA, Ainsworth ME, Pilcher MF. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Am. 1977 ; 59 (4). 496-500
8. Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med. 1988 ; 85 (4A). 57-61
9. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011 ; 13 (1). 77-80
10. Belizna CC, Richard V, Thuillez C, Levesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev. 2007 ; 7 (1). 46-51
11. Ammirati E, Bozzolo EP, Contri R, et al. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis. 2014 ; 24 (7). 751-759
12. Salinas MJ, Bertoli AM, Lema L, et al. Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in argentina. J Clin Rheumatol. 2013 ; 19 (8). 439-443
13. Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012 ; 14 (3). R135
14. Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014 ; 30 (7). 1257-1266
15. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007 ; 298 (2). 187-193
16. Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2011 ; 63 (4). 530-534
17. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 ; 41 (6). 961-965
18. de la Cruz JP, Guerrero A, Gonzalez-Correa JA, Marquez E, Nacle I, Sanchez de la Cuesta F. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Eur J Clin Pharmacol. 2002 ; 57 (11). 775-780
19. Catella F, Healy D, Lawson JA, FitzGerald GA. 11-dehydrothromboxane b2: a quantitative index of thromboxane a2 formation in the human circulation. Proc Natl Acad Sci USA. 1986 ; 83 (16). 5861-5865
20. Ben-Chetrit E, Fischel R, Hinz B, Levy M. The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases cox-1 and cox-2. Rheumatol Int. 2005 ; 25 (5). 332-335
21. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane a(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem. 1999 ; 274 (41). 29108-29114
22. Prowse C, Pepper D, Dawes J. Prevention of the platelet alpha-granule release reaction by membrane-active drugs. Thromb Res. 1982 ; 25 (3). 219-227
23. Rosado JA. Acidic Ca(2+) stores in platelets. Cell Calcium. 2011 ; 50 (2). 168-174
24. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996 ; 5: S4 - S10
25. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in t cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000 ; 95 (11). 3460-3466
26. Okwuosa TM, Klein O, Chan C, et al. 13-year long-term associations between changes in traditional cardiovascular risk factors and changes in fibrinogen levels: the coronary artery risk development in young adults (cardia) study. Atherosclerosis. 2013 ; 226 (1). 214-219
27. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993 ; 118 (12). 956-963
28. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 ; 294 (14). 1799-1809
29. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006 ; 15 (5). 268-275
30. Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin 1 alpha (il-1-alpha) and il-6 in human monocytes and t cells. J Rheumatol. 1993 ; 20 (5). 803-808
31. Gupta JD, Gruca M, Ablett W. Effect of other drugs and chemicals on the degradation of aspirin in vitro: possible extrapolation to in vivo metabolism of aspirin. Eur J Drug Metab Pharmacokinet. 1979 ; 4 (2). 103-108
32. Bengtsson C, Andersson SE, Edvinsson L, Edvinsson ML, Sturfelt G, Nived O. Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus. Basic Clin Pharmacol Toxicol. 2010 ; 107 (6). 919-924
33. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci. 2007 ; 1108: 24-34
34. Ernst E, Rose M, Lee R. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect. Pharmatherapeutica. 1984 ; 4 (1). 48-52